SIM
PTGX icon

Spark Investment Management’s Protagonist Therapeutics PTGX Stock Holding History

Spark Investment Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-23,303
Closed -$164K – 219
2020
Q1 		$164K Sell
23,303
-597
-2% -$4.47K 0.09% 244
2019
Q4 		$168K Buy
+23,900
New +$237K 0.02% 476
2019
Q2 		– Sell
-10,100
Closed -$126K – 673
2019
Q1 		$126K Sell
10,100
-84,500
-89% -$746K 0.01% 553
2018
Q4 		$636K Sell
94,600
-44,200
-32% -$351K 0.04% 364
2018
Q3 		$1.43M Buy
138,800
+500
+0.4% +$4.3K 0.08% 321
2018
Q2 		$929K Buy
138,300
+56,600
+69% +$435K 0.05% 380
2018
Q1 		$701K Buy
81,700
+60,200
+280% +$1.13M 0.04% 372
2017
Q4 		$447K Buy
+21,500
New +$381K 0.02% 471
2017
Q2 		– Sell
-31,500
Closed -$403K – 846
2017
Q1 		$403K Hold
31,500
– – 0.03% 577
2016
Q4 		$692K Sell
31,500
-10,600
-25% -$236K 0.06% 415
2016
Q3 		$889K Buy
+42,100
New +$575K 0.07% 379

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Spark Investment Management's PTGX Position: Q2 2020 in Review

Spark Investment Management sold out of Protagonist Therapeutics (PTGX) in Q2 2020, closing a stake of 23,303 shares — an estimated $164K sold.

Spark Investment Management first reported a position in PTGX in Q3 2016 and held it in 11 quarters. The position peaked at $1.43M in Q3 2018. 85 funds tracked by Wall St. Rank hold PTGX as of Q2 2020.

  • Spark Investment Management reported no remaining Protagonist Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Spark Investment Management sold 23,303 Protagonist Therapeutics shares in Q2 2020, an estimated $164K.
  • Spark Investment Management first reported a position in Protagonist Therapeutics in Q3 2016 and held it in 11 quarters.
  • Spark Investment Management's Protagonist Therapeutics position peaked at $1.43M in Q3 2018.
  • 85 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2020.

Based on Spark Investment Management's 13F filing for Q2 2020, filed 12 Aug 2020.